URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
UroGen Pharma Ltd. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Jelmyto [Member] | $93.99M | $90.40M | $82.71M | $64.36M | $48.04M | $11.80M | 85.6% | +4.0% |
| Zusduri [Member] | $15.80M | $0 | – | – | – | – | 14.4% | – |
By region
From the segment and revenue-disaggregation notes of UroGen Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.